246 related articles for article (PubMed ID: 12941722)
1. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
Diabetes Care; 2003 Sep; 26(9):2581-7. PubMed ID: 12941722
[TBL] [Abstract][Full Text] [Related]
2. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
4. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.
Meneilly GS; Greig N; Tildesley H; Habener JF; Egan JM; Elahi D
Diabetes Care; 2003 Oct; 26(10):2835-41. PubMed ID: 14514588
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
7. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
8. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
9. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
Vilsbøll T; Agersø H; Krarup T; Holst JJ
J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
[TBL] [Abstract][Full Text] [Related]
10. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
12. Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis.
Hedetoft C; Sheikh SP; Larsen S; Holst JJ
Pancreas; 2000 Jan; 20(1):25-31. PubMed ID: 10630380
[TBL] [Abstract][Full Text] [Related]
13. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
14. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
15. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
Gutniak MK; Linde B; Holst JJ; Efendić S
Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
Zander M; Christiansen A; Madsbad S; Holst JJ
Diabetes Care; 2004 Aug; 27(8):1910-4. PubMed ID: 15277416
[TBL] [Abstract][Full Text] [Related]
19. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
20. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
